Get the Stockscreener App
1.19
4.40%
-0.06
Mira Pharmaceuticals Inc stock is traded at $1.19, with a volume of 422.44K.
It is down -4.40% in the last 24 hours and up +3.02% over the past month.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
See More
Previous Close:
$1.25
Open:
$1.255
24h Volume:
422.44K
Relative Volume:
1.21
Market Cap:
$20.06M
Revenue:
-
Net Income/Loss:
$-11.24M
P/E Ratio:
-1.5627
EPS:
-0.7615
Net Cash Flow:
$-4.79M
1W Performance:
+18.32%
1M Performance:
+3.02%
6M Performance:
-11.48%
1Y Performance:
-2.85%
1-Day Range:
$1.11
$1.255
1-Week Range:
$0.9039
$1.328
52-Week Range:
$0.51
$5.01
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Name
Mira Pharmaceuticals Inc
Sector
Industry
Phone
813-369-5150
Address
1200 BRICKELL AVENUE, MIAMI
Compare MIRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
1.19 | 20.06M | 0 | -11.24M | -4.79M | -0.7615 |
|
LLY
Lilly Eli Co
|
808.05 | 725.80B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
211.69 | 373.58B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
161.96 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
76.15 | 336.79B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
93.69 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
Mira Pharmaceuticals Inc Stock (MIRA) Latest News
Mira Pharmaceuticals expands pain management pipeline By Investing.com - Investing.com Australia
Mira Pharmaceuticals Develops Topical Formulation of Ketamir-2 for Pain Relief -March 13, 2025 at 09:30 am EDT - Marketscreener.com
Mira Pharmaceuticals succesfully develops topical version of its therapy for localized neuropathic and inflammatory pain - Marketscreener.com
MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain - Corsicana Daily Sun
Revolutionary Topical Pain Treatment: MIRA's Ketamir-2 Targets Multiple Pain Conditions - StockTitan
EXCLUSIVE: MIRA Pharmaceuticals Expands Pipeline, Enhances Value Proposition With Development Of Topical Formulation For Lead Pain Treatment Candidate - Benzinga
What is Zacks Small Cap’s Forecast for MIRA FY2024 Earnings? - Defense World
Mira Pharmaceuticals begins phase 1 trial for pain treatment By Investing.com - Investing.com Australia
SponsoredImpartialComprehensive - Research Tree
Urgent Boots paracetamol recall after packets found to contain a different drug - AOL
Mira Pharmaceuticals Announces Approval And Initiation Of Phase 1 Clinical Trial For Ketamir-2 In Neuropathic Pain - Marketscreener.com
Mira Pharmaceuticals begins phase 1 trial for pain treatment - Investing.com
Mira Pharmaceuticals announces approval, initiation of Phase 1 Ketamir-2 trial - TipRanks
MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain - accessnewswire.com
Can This Novel Ketamine Analog Outperform Gabapentin? MIRA's Neuropathic Pain Drug Enters Clinical Trials - StockTitan
EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain - Benzinga India
Tiziana stock jumps 12% on TBI drug study publication - MSN
A little-known Chinese company made a drug that beat the world’s biggest-selling medicine - AOL
Mira Murati's new AI startup poaches 20 OpenAI researchers - Reuters
MediPharm Labs terminates proposed sale of Napanee facility to Kensana Health - Seeking Alpha
Microstrategy Inc. – 8% PRF PERPETUAL USD 100 – Ser A’s (STRK) Stock: A Week-by-Week Analysis - The News Heater
Monday.Com Ltd (MNDY) Shares Down Despite Recent Market Volatility - The News Heater
Mira Pharmaceuticals Inc (MIRA) Stock: Evaluating the Market Performance - The News Heater
Vanda Pharmaceuticals Inc (VNDA) Shares Rise Despite Market Challenges - The News Heater
Air Transport Services Group Inc (ATSG) Stock: Evaluating the Market Performance - The News Heater
Report: OpenAI's ex-CTO, Mira Murati, has recruited OpenAI co-founder John Schulman - Yahoo Finance
OpenAI cofounder John Schulman is joining Mira Murati’s startup after brief stint at Anthropic - Yahoo Finance
Kernel and Mira Launch Industry’s First $300M Secured AI API - GlobeNewswire Inc.
Mira Network Launches $10M Grant Program for AI Builders - EIN News
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy? - AOL
UCalgary researchers to validate Mira Hormone Monitor - Yahoo Finance
TEVA Stock Drops Over 5% Amid Financial Struggles - GuruFocus.com
MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End - ACCESS Newswire
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA - ACCESS Newswire
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.18% - MSN
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study - ACCESS Newswire
MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance - ACCESS Newswire
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025 - ACCESS Newswire
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development - ACCESS Newswire
MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain - ACCESS Newswire
Wealth Enhancement Advisory Services LLC Acquires 6,454 Shares of PPL Co. (NYSE:PPL) - Defense World
International Assets Investment Management LLC Invests $29,000 in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) - Defense World
MIRA Pharmaceuticals (NASDAQ:MIRA) Shares Down 1.7% – Should You Sell? - Defense World
AMRN Stock Rises Over 5% Amidst Lack of Institutional Ratings - GuruFocus.com
Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation - Yahoo Finance
Cocrystal stock plunges 40% on influenza drug update (COCP:NASDAQ) - Seeking Alpha
Traws stock plunges 43% on financing update (TRAW:NASDAQ) - Seeking Alpha
Zacks Small Cap Has Pessimistic Outlook of MIRA Q4 Earnings - Defense World
Mira Pharmaceuticals appoints new accounting firm By Investing.com - Investing.com South Africa
Mira Pharmaceuticals appoints new accounting firm - Investing.com
Why Wall Street Expects This Growth Stock To Soar 99% In 2025 - Barchart
Mira Pharmaceuticals Inc Stock (MIRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):